Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (6587)

6/26/1998 9:22:00 PM

From: aknahow

Respond to of 17367

More on LBP:

Clinical and Diagnostic Laboratory Immunology, Mar. 1997, p. 113-116
1071-412X/97/$04.00+0
Copyright c 1997, American Society for Microbiology
Vol. 4, No. 2

The Level of Lipopolysaccharide-Binding Protein Is Significantly
Increased in Plasma in Patients with the Systemic Inflammatory
Response Syndrome

Andrzej Myc,1 Jochen Buck,2 Joyce Gonin,1 Brian Reynolds,3
Ulrich Hammerling,4 and David Emanuel1

Section of Pediatric Hematology-Oncology and Stem Cell Transplantation Program, Wells Center for
Pediatric Research, Riley Hospital for Children, Indiana University Medical Center, Indianapolis,
Indiana1; Cornell University Medical College, New York, New York2; Department of Biology, Alma
College, Alma, Michigan3; and Memorial Sloan Kettering Cancer Center, New York, New York4

Received 12 July 1996/Returned for modification 21 October 1996/Accepted 7 November 1996

Currently, there is no way to predict with a high degree of sensitivity and specificity which patients are likely to develop
systemic inflammatory response syndrome (SIRS) following systemic infection, trauma, organ rejection, or blood loss.
The level of human lipopolysaccharide-binding protein (LBP) was determined in the plasma of 22 patients with a clinical
diagnosis of early SIRS. Twenty-nine plasma samples from healthy volunteers were used as controls. The mean level of
LBP in the plasma of healthy volunteers was 7.7 æg/ml (standard deviation, 6.2 æg/ml). Twenty-one of 22 patients
(95%) with SIRS had an LBP level on admission at least 2 standard deviations above the mean LBP level for a healthy
volunteer control group (range, 4.9 to 114.2 æg/ml; mean, 36.6 æg/ml; standard deviation, 22.2 æg/ml; P < 0.0001).
The level of LBP in the plasma of the majority of patients with early SIRS is significantly increased compared to that in
healthy controls. The sensitivity, specificity, and predictive value of elevated plasma LBP levels in patients with SIRS
remain to be determined.

[Next] [CDLI Issue List] [ASM Home Page] [Subscription Information] [Instructions for Authors]
[Search]